Valvular heart diseases (VHDs) are currently treated using either mechanical or
bioprosthetic heart valves. Unfortunately, mechanical valves require lifelong anticoagulation …

Calcific aortic valve disease is dramatically increasing in global burden, yet no therapy
exists outside of prosthetic replacement. The increasing proportion of younger and more …

Over the last 20 years, the designs of tissue engineered heart valves have evolved
considerably. An initial focus on replicating the mechanical and structural features of …

Cardiovascular tissue engineering and regeneration strive to provide long-term, effective
solutions for a growing group of patients in need of myocardial repair, vascular (access) …

Aims Donor heart shortage leads to increasing use of left ventricular assist device (LVAD) as
bridge‐to‐transplant or destination therapy. Prolonged LVAD support is associated with …

Replacing diseased valves with bioprosthetic heart valves (BHVs) is an increasingly
recognized treatment for valvular heart disease (VHD) due to the increasing application of …

Background Calcific aortic valve disease (CAVD) causes an increasing health burden in the
21st century due to aging population. The complex pathophysiology remains to be …

Heart valve leaflets are complex structures containing valve endothelial cells, interstitial
cells, and extracellular matrix. Heart valve endothelial cells sense mechanical stimuli, and …

Cardiovascular tissue engineering (CVTE) aims to create living tissues, with the ability to
grow and remodel, as replacements for diseased blood vessels and heart valves. Despite …

Calcific aortic valve disease (CAVD) is an athero-inflammatory process. Growing evidence
supports the inflammation-driven calcification model, mediated by cytokines such as …